


PB60564USw

In the Claims:

Please cancel claims 1-15. Please add new claims 16-37.

1-15. (Canceled)


16. (New) A compound of formula (I)



wherein

---- represents a single or a double bond;

R is a radical selected from:



in which R_1 is halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3;

 R_2 is hydrogen or C_{1-4} alkyl; R_3 is hydrogen, hydroxy or C_{1-4} alkyl; R_4 is hydrogen or R_4 together with R_3 is $=O$ or $=CH_2$;

R_5 is phenyl, naphthyl, a 9 to 10 membered fused bicyclic heterocyclic group or a 5 or 6 membered heteroaryl group, wherein said groups are optionally substituted by 1 to 3 groups independently selected from trifluoromethyl, C_{1-4} alkyl, hydroxy, cyano, C_{1-4} alkoxy, trifluoromethoxy, halogen or $S(O)_q C_{1-4}$ alkyl;

 R_6 and R_7 independently are hydrogen, cyano, C_{1-4} alkyl; R_8 is $(CH_2)_r R_{10}$;

R_9 is hydrogen, halogen, C_{3-7} cycloalkyl, hydroxy, nitro, cyano or C_{1-4} alkyl optionally substituted by one or two groups selected from halogen, cyano, hydroxy or C_{1-4} alkoxy;

 R_{10} is hydrogen or C_{3-7} cycloalkyl;

PB60564USw

n is 1 or 2;


q is 0, 1 or 2;

r is 0 or an integer from 1 to 4;

or a pharmaceutically acceptable salt or a solvate thereof.

17. (New) A compound as claimed in claim 1 wherein n is 2.

18. (New) A compound as claimed in claim 1 wherein R is:



wherein R_1 is halogen, C_{1-4} alkyl, cyano, C_{1-4} alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3.

19. (New) A compound as claimed in claim 1 wherein R_5 is phenyl or naphthyl optionally substituted by one or two groups selected from trifluoromethyl, cyano, C_{1-4} alkyl or halogen.

20. (New) A compound as claimed claim 1 wherein R_8 is $(CH_2)_r R_{10}$ wherein R_{10} is hydrogen or C_{3-7} cycloalkyl and r is 0 or 1.

21. (New) A compound as claimed in claim 1, wherein R_9 is hydrogen or C_{1-4} alkyl optionally substituted by one or two halogens.

22. (New) A compound as claimed in claim 1 wherein:

R is phenyl substituted by a fluorine;

R_2 , R_9 and R_4 are each hydrogen;

R_3 is hydrogen, hydroxy or methyl, or R_3 together with R_4 is =O or =CH₂;

R_6 and R_7 are independently hydrogen or methyl;

R_5 is phenyl or naphthyl optionally substituted by one or two groups independently selected from cyano, methyl, chlorine, bromine or fluorine atom;

R_8 is hydrogen, methyl or cyclopropylmethyl; and

n is 2.

PB60564USw

23. (New) A compound selected from:

- 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one;
- 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one ;
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one (Chain Enantiomer 1);
- 1-[(1S)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one ;
- 1-[(3-Chloro-1-naphthalenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one;
- 4-({3-[4-(4-Fluorophenyl)-4-piperidiny]-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)methyl}-2-naphthalenecarbonitrile;
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one (Chain Enantiomer 2);
- 1-[(1R)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one;
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one (Chain Enantiomer 1);
- 1-[(1S)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one ;
- 1-[(3-Chloro-1-naphthalenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one;
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one (Chain Enantiomer 2);
- 1-[(1R)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one;
- 4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)methyl}-2-naphthalenecarbonitrile;
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one hydrochloride (Chain Enantiomer 1);
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one hydrochloride (Chain Enantiomer 1);
- 1-[(3-Chloro-1-naphthalenyl)methyl]-3-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one;

PB60564USw

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-2-pyrrolidinone
1-[(1S)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-2-
pyrrolidinone (Diastereoisomer 1);
1-[(1S)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-2-
pyrrolidinone;
1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-2-pyrrolidinone
(Diastereoisomer 1 Chain Enantiomer 1);
1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-2-pyrrolidinone
(Diastereoisomer 2 Chain Enantiomer 1);
1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-2-pyrrolidinone
(Diastereoisomer 1 Chain Enantiomer 2);
1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-2-pyrrolidinone
(Diastereoisomer 2 Chain Enantiomer 2);
4-({3-[4-(4-Fluorophenyl)-4-piperidiny]-2-oxo-1-pyrrolidiny)methyl}-2-
naphthalenecarbonitrile (Enantiomer 1);
4-({3-[4-(4-Fluorophenyl)-4-piperidiny]-2-oxo-1-pyrrolidiny)methyl}-2-
naphthalenecarbonitrile (Enantiomer 2);
7-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidiny]-2-oxo-1-pyrrolidiny)methyl}-2-
naphthalenecarbonitrile (Enantiomer 2);
6-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidiny]-2-oxo-1-pyrrolidiny)methyl}-2-
naphthalenecarbonitrile (Enantiomer 2);
7-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidiny]-2-oxo-1-pyrrolidiny)methyl}-2-
naphthalenecarbonitrile (Enantiomer 1);
6-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidiny]-2-oxo-1-pyrrolidiny)methyl}-2-
naphthalenecarbonitrile (Enantiomer 1);
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-
pyrrolidinone;
1-[1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-
pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);
1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-
pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 1);
1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-
pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);
1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-
pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 2);

PB60564USw

- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 2);
- 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-pyrrolidinone (Enantiomer 1);
- 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-pyrrolidinone (Enantiomer 2);
- 4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-1-pyrrolidiny})methyl)-2-naphthalenecarbonitrile (Enantiomer 1);
- 4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-1-pyrrolidiny})methyl)-2-naphthalenecarbonitrile (Enantiomer 2);
- 7-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-1-pyrrolidiny})methyl)-2-naphthalenecarbonitrile (Enantiomer 2);
- 6-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-1-pyrrolidiny})methyl)-2-naphthalenecarbonitrile;
- 7-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-1-pyrrolidiny})methyl)-2-naphthalenecarbonitrile (Enantiomer 1);
- 6-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-1-pyrrolidiny})methyl)-2-naphthalenecarbonitrile (Enantiomer 1);
- 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1H-pyrrole-2,5-dione;
- 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-5-methylidene-1,5-dihydro-2H-pyrrol-2-one;
- and pharmaceutically acceptable salts or solvates thereof.

24. (New) A compound according to claim 23 in amorphous or crystalline form.

25. (New) A compound selected from:

- 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one;
- 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one hydrochloride;
- 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one fumarate;
- 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one citrate.

PB60564USw

26. (New) A compound according to claim 25 in crystalline form.
27. (New) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one citrate.
28. (New) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one.
29. (New) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more pharmaceutically acceptable carriers or excipients.
30. (New) A pharmaceutical composition comprising a compound as claimed in claim 25 in admixture with one or more pharmaceutically acceptable carriers or excipients.
31. (New) A pharmaceutical composition comprising a compound as claimed in claim 28 in admixture with one or more pharmaceutically acceptable carriers or excipients.
32. (New) A method for the treatment of a psychotic disorder in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.
33. (New) A method for the treatment of depression or mood disorders in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.
34. (New) A method for the treatment of an anxiety disorder in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.
35. (New) A method for treatment of rheumatoid arthritis in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.

PB60564USw

36. (New) A method for treatment of rheumatoid arthritis in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 25.

37. (New) A method for treatment of rheumatoid arthritis in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 28.